Amphastar Pharmaceuticals

AMPH

Market cap $855M

ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.

Amphastar Pharmaceuticals NASDAQ: AMPH is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice President of Finance Bill Peters told investors at the East Coast IDEAS Conference.

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Amphastar Pharmaceuticals NASDAQ: AMPH executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China business.

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.

Amphastar Pharmaceuticals NASDAQ: AMPH executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.7 per share. This compares to earnings of $0.74 per share a year ago.